ticagrelor

Drugmaker recalls samples of antiplatelet drugAstraZeneca voluntarily recalls professional samples of its antiplatelet agent. Here's what to do.
USPSTF updates recommendations for aspirin useThe guidelines, which update the group's 2007 and 2009 recommendations, are published in the "Annals of Internal Medicine."
FDA expands Brilinta approval for long-term use in patients with heart attack historyFDA has expanded approval for ticagrelor (Brilinta, AstraZeneca) to include long-term use in patients with a history of heart attack.
FDA grants priority review to expand use of BrilintaThe FDA has granted Priority Review for ticagrelor (Brilinta, AstraZeneca) for patients with a history of heart attack.
Dual antiplatelet therapy lowers risk of CV death in MI secondary preventionSecondary prevention of MI still calls for a careful balancing act between risks and benefits.
FDA drug approvals-April 2015FDA actions in brief, priority review, breakthrough therapy designation, fast-track designations, orphan drug designations, first-time generic approvals
FDA approves new administration option for BrilintaFDA has approved a new administration option for ticagrelor (Brilinta, AstraZeneca) in acute coronary syndrome patients.
FDA opens up generic competitionFDA released new draft guidance designed to make it easier for generic manufacturers to introduce competition to 38 existing drug products, according to the agency’s Federal Register notice.
FDA drug approvals-March 2015FDA actions in brief, breakthrough designation, recommended for approval, priority review, fast-track designations